CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, hematology-oncology fellows, medical oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of follicular lymphoma (FL).
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with follicular lymphoma.
  
  LEARNING OBJECTIVES

  • Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory (R/R) FL.
  • Develop an understanding of available clinical trial findings supporting the use of bispecific antibodies targeting CD20 and CD3 for the management of R/R FL.
  • Identify patients with R/R FL who may be candidates for chimeric antigen receptor T-cell therapy directed at CD19.
  • Assess recently presented clinical research findings with the use of CD19-targeted monoclonal antibodies in combination with immunomodulatory agents in the care of patients with R/R FL.
  • Evaluate published clinical research findings establishing the efficacy and safety of combined Bruton tyrosine kinase inhibitor/anti-CD20 antibody therapy for patients with R/R FL.
  • Consider recommended approaches to prevent, ameliorate and manage toxicities associated with various therapies commonly used in the care of patients with R/R FL.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

  ACCREDITATION, SUPPORT AND CREDIT STATEMENT
  In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
  
  PHYSICIAN CREDIT DESIGNATION STATEMENT
  Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation components, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS). For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  NURSING CONTINUING PROFESSIONAL DEVELOPMENT
  Successful completion of this nursing continuing professional development activity will be awarded 1.25 contact hours and 1.25 contact hours in the area of pharmacology.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/SOHO2025/FollicularLymphoma/Sep5/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  CONTINUING PHARMACY EDUCATION
  Medical Learning Institute Inc designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
  Universal Activity Number: JA0007322-0000-25-048-H01-P
  
  For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the National Association of Boards of Pharmacy (NABP) only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CE ACTIVITY
  To receive credit for an activity in this series, the participant should review the CME, NCPD or ACPE information, listen to or view the recording, review the downloadable slide set, complete the post-test with a score of 80% or better (CME and NCPD only) and fill out the evaluation. Evaluation location URLs are noted below:
  CME Evaluations: ResearchToPractice.com/SOHO2025/FL/CME (audio), ResearchToPractice.com/SOHO2025/FL/Video/CME (video)
  NCPD Evaluations: ResearchToPractice.com/SOHO2025/FL/NCPD (audio), ResearchToPractice.com/SOHO2025/FL/NCPD/Video (video)
  ACPE Evaluations: ResearchToPractice.com/SOHO2025/FL/ACPE (audio), ResearchToPractice.com/SOHO2025/FL/ACPE/Video (video)
  
  DISCLOSURE & CONFLICT OF INTEREST POLICY
  Medical Learning Institute Inc (MLI) and Research To Practice (RTP) are committed to providing high-quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Jennifer Crombie, MD
  Assistant Professor of Medicine
  Harvard Medical School
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committees: Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, ADC Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Kite, A Gilead Company, Lilly, Novartis, Regeneron Pharmaceuticals Inc.
  
  Laurie H Sehn, MD, MPH
  Chair, Lymphoma Tumour Group
  BC Cancer Centre for Lymphoid Cancer
  Clinical Professor of Medicine
  Division of Medical Oncology
  University of British Columbia
  Podcast Editor, Blood
  Vancouver, British Columbia, Canada
  
  Consulting/Honoraria: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, CARGO Therapeutics, Chugai Pharmaceutical Co Ltd, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, Seagen Inc; Contracted Research: Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: CARGO Therapeutics.
  
  SURVEY PARTICIPANTS — John N Allan, MD — Advisory Committees: NeoGenomics; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company; Contracted Research: BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Merck; Speakers Bureaus: AbbVie Inc, BeOne. Ann LaCasce, MD, MMSc — Advisory Committees: Genmab US Inc, Kite, A Gilead Company; Consulting Agreements: Pierre Fabre, Takeda Pharmaceuticals USA Inc. Loretta J Nastoupil, MD — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Genentech, a member of the Roche Group; Contracted Research: BeOne, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Genentech, a member of the Roche Group.
  
  MODERATOR
  Jeremy S Abramson, MD, MMSc
  Director, Center for Lymphoma
  Massachusetts General Hospital
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Miltenyi Biotec, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.
  
  PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.
  
  This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
  
  Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
  
  This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, Novartis, and Regeneron Pharmaceuticals Inc.
  
  Release date: October 10, 2025
  Expiration date: October 10, 2026
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.